Agrawal 2009.

Methods	Prospective, randomised, placebo‐controlled, single centre study
Participants	150 patients ( 50 alfuzosin, 50 tamsulosin, 50 placebo), mean age 69, 72 and 71 years respectively (aged 48 to 90 years)
Interventions	A (50): Alfuzosin 10 mg OD B (50): Tamsulosin 0.4 mg C (50): Placebo, Then TWOC after 3 days
Outcomes	Number who had successful TWOC: A 33/50, B   35/50, C 18/50 Initial catheterisation volume American Urological Association score Post void residual urinary volume (mL) Peak urinary flow rate (mL/sec) Adverse effects
Notes	Second trial phase: successful TWOC patients continued in respective treatment groups and followed up at 1 week, 2 weeks, 1 month and 3 months.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not specified: '...randomized into three groups.'
Allocation concealment (selection bias)	Unclear risk	Not specified
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	More detail in tables of analysis needed.
Selective reporting (reporting bias)	Unclear risk	All the outcomes as detailed in the method section of the trial were reported in the result section. Some outcomes which are considered important from patients’ perspective were not reported. Without the protocol it was difficult to judge whether or not these outcomes were included in the protocol and not reported in the report.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not specified
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not specified
Other bias	Unclear risk	Other aspects of trial design such as baseline comparability, sample size calculation, use of intention‐to‐treat analysis and financial support were inadequately or not at all specified.